ArticlePediatric nephrology (Berlin, Germany)2009
Analyses of age, gender and other risk factors of erythropoietin resistance in pediatric and adult dialysis cohorts.
Article in Pediatric nephrology (Berlin, Germany), 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06053866 (Prevalence of Erthropoietin Stimulating Agents Hyporesponsiveness and Its Correlation With Cardiovascular Morbidities in Hemodialysis Patients in Assiut University Hospital), which is not on this map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Prevalence of Erthropoietin Stimulating Agents Hyporesponsiveness and Its Correlation With Cardiovascular Morbidities in Hemodialysis Patients in Assiut University Hospital
Who cites it
21 citing papers in PubMed, 41 citations in OpenAlex.
- Erythropoietin resistance among pediatric patients on chronic hemodialysis: A cross-sectional study.Pediatric nephrology (Berlin, Germany) · 2025Article
- Assessment of myeloid response and iron status among Sudanese pediatric ESKD on hemodialysis through reticulocyte parameters and β-globin mRNA expression.BMC nephrology · 2024Observational
- Use of erythropoiesis-stimulating agents in children with chronic kidney disease: a systematic review.Clinical kidney journal · 2022Review
- Successful treatment of anti-EPO antibody associated refractory anemia with hypoxia-inducible factor prolyl hydroxylase inhibitor.Renal failure · 2020Article
- HIF stabilizers in the management of renal anemia: from bench to bedside to pediatrics.Pediatric nephrology (Berlin, Germany) · 2019Review
- Interleukin-6 Contributes to the Development of Anemia in Juvenile CKD.Kidney international reports · 2019Article
- Response to erythropoietin in pediatric patients with chronic kidney disease: insights from an in vitro bioassay.Pediatric nephrology (Berlin, Germany) · 2018Article
- Anemia in chronic kidney disease.Pediatric nephrology (Berlin, Germany) · 2018Review
- Circulating growth arrest-specific protein 6 levels are associated with erythropoietin resistance in hemodialysis patients.SpringerPlus · 2016Article
- Association of plasma F2-isoprostanes and isofurans concentrations with erythropoiesis-stimulating agent resistance in maintenance hemodialysis patients.BMC nephrology · 2015Article
- Association of higher erythropoiesis stimulating agent dose and mortality in children on dialysis.Pediatric nephrology (Berlin, Germany) · 2014Article
- An emerging need for developing new models for myocardial infarction as a chronic complex disease: lessons learnt from animal vs. human studies on cardioprotective effects of Erythropoietin in reperfused myocardium.Frontiers in physiology · 2014Article
- Chapter 3: Use of ESAs and other agents to treat anemia in CKD.Kidney international supplements · 2012Article
- Resistance to erythropoietin-stimulating agents: etiology, evaluation, and therapeutic considerations.Pediatric nephrology (Berlin, Germany) · 2012Review
- Hepcidin in anemia of chronic kidney disease: review for the pediatric nephrologist.Pediatric nephrology (Berlin, Germany) · 2012Review
- Anemia in children with chronic kidney disease.Nature reviews. Nephrology · 2011Review
- Risk factors for high erythropoiesis stimulating agent resistance index in pre-dialysis chronic kidney disease patients, stages 4 and 5.International urology and nephrology · 2011Article
- No difference in meeting hemoglobin and albumin targets for dialyzed children with urologic disorders.Pediatric nephrology (Berlin, Germany) · 2011Article
- Risk for anemia in pediatric chronic kidney disease patients: a report of NAPRTCS.Pediatric nephrology (Berlin, Germany) · 2010Article
- Target hemoglobin trials in chronic kidney disease: design and interpretation issues.Pediatric nephrology (Berlin, Germany) · 2009Review
Corrections and comments
- Commented on by
Authors and funding
3 authors at 3 institutions in 1 country.
Funding
Abstract
Previous studies often report lower responses to erythropoietin (EPO) therapy in pediatric patients on chronic dialysis than those of adults. Because of the greater capacity for hematopoiesis in the younger population, these studies may be confounded by poorly identified variables. Thus, we made parallel studies of pediatric and adult cohorts to explore the relationship between age, gender and other risk factors with EPO resistance. Thirty pediatric subjects (aged 8-20 years) and 66 adult subjects (aged 22-85 years) on chronic hemodialysis and EPO were enrolled. After stratification by 50th percentile of EPO response, the best predictive model was identified by backward elimination of the risk factors with the least contribution to the regression. Relationship between age, gender and EPO resistance was examined by analysis of covariance (ANCOVA). The most predictive model of EPO response for the pediatric cohort had, as the major variables, urea clearance x dialysis duration/total body water (Kt/V), urea reduction ratio (URR), intact parathyroid hormone (iPTH), blood loss, normalized protein catabolic rates (nPCR) and indices of malnutrition and inflammation, whereas adults had iron and folate deficiencies as the dominant variables. Although EPO resistance was more common in female subjects than in male subjects, relationship with neither age nor gender was significant. Furthermore, the prescription of a larger (initiating) EPO dose by pediatric physicians compared with adult nephrologists confounded the interaction between age and EPO resistance. In summary EPO resistance in the pediatric dialysis cohort was predicted by nutritional deficits, inflammation, poor dialysis, and hyperparathyroidism, while iron and folate deficits were the major determinants in adults. Although confounded by the pattern of EPO prescription, neither age nor gender was predictive of EPO resistance in the two study groups.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.